Related Experiment Video
Updated: May 22, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Abstract:
One of the major challenges in the evaluation of new therapies for lymphoma and other hematologic malignancies has been the ability to demonstrate changes in important biomarkers and pharmacodynamic end points in the tumor cell population.In this issue of Blood, Leonard et al provide an elegant evaluation of the cyclin-dependent kinase (cdk) inhibitor PD0332991 in patients with relapsed mantle cell lymphoma. Their results suggest that the combination of functional imaging using fluorothymidine–positron emission tomography (FLT-PET) and immunohistochemistry can provide important information about target inhibition in tumor cells, and the effects this inhibition has on proliferation and metabolism.
Insights
Evaluating new lymphoma therapies is challenging. Combining fluorothymidine–positron emission tomography (FLT-PET) imaging and immunohistochemistry effectively shows how cyclin-dependent kinase (cdk) inhibitors impact tumor cells in mantle cell lymphoma.
Area of Science:
- Oncology
- Hematology
- Pharmacodynamics
Background:
- Evaluating novel therapies for hematologic malignancies, including lymphoma, requires robust methods to assess biomarker and pharmacodynamic changes within tumor cells.
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with limited treatment options for relapsed disease.
Discussion:
- Leonard et al. investigated the cyclin-dependent kinase (cdk) inhibitor PD0332991 in patients with relapsed MCL.
- The study highlights the utility of combining functional imaging, specifically fluorothymidine–positron emission tomography (FLT-PET), with immunohistochemistry.
- This combined approach provides critical insights into target inhibition within tumor cells.
Key Insights:
- The combination of FLT-PET and immunohistochemistry serves as a valuable tool for assessing drug efficacy in vivo.
- Demonstrated target inhibition by PD0332991 in tumor cells, affecting proliferation and metabolism.
- Provides a framework for evaluating other targeted therapies in hematologic malignancies.
Outlook:
- Further validation of this imaging and biomarker strategy in larger clinical trials is warranted.
- This approach can accelerate the development of new targeted therapies for lymphoma and other blood cancers.
- Potential for improved patient stratification and personalized treatment strategies based on pharmacodynamic response.
